葛兰素史克起诉辉瑞、BioNTech就COVID-19疫苗专利

GSK (NYSE:GSK) is reportedly suing Pfizer (PFE) and partner BioNTech (BNTX) for patent infringement over the use of certain mRNA technology for their COVID-19 Comirnaty vaccines.

GSK, also known as GlaxoSmithKline, filed the suit in a Delaware federal court on Thursday, alleging that Pfizer and BioNTech's Comirnaty vaccines infringe upon vaccine technology developed by GSK, according to Reuters.

A Pfizer spokesperson told Reuters that the company was confident in its intellectual property position on the vaccines and would vigorously defend itself against the claims in court.

The case is the latest filed by GSK against Pfizer over technology used in its vaccines. Last year, GSK sued Pfizer, alleging that Pfizer’s RSV vaccine Abrysvo infringed upon GSK’s patents for its RSV vaccine Arexvy.

In 2022, COVID-19 vaccine developer Moderna (MRNA) also sued Pfizer and BioNtech for patent infringement over Comirnaty. The case is ongoing.